TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating yesterday.
Phil Nadeau has given his Buy rating due to a combination of factors related to Kura Oncology’s recent developments and strategic plans. The company has reported positive topline results from its pivotal Phase II KOMET-001 trial for ziftomenib in relapsed/refractory NPM1 mutant AML, achieving its primary endpoint with statistical significance. This success positions ziftomenib on a promising path toward FDA approval, with a New Drug Application (NDA) submission planned for the second quarter.
Furthermore, Kura has reached alignment with the FDA and EMA on the design of its Phase III KOMET-017 program, which will explore ziftomenib in combination with standard-of-care chemotherapy for different AML populations. This program is set to initiate in the second half of 2025, with initial data expected by 2028. These strategic advancements, coupled with the company’s strong cash position, underpin Nadeau’s confidence in Kura Oncology’s growth potential, leading to his Buy rating.
Nadeau covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Neurocrine, and Dynavax. According to TipRanks, Nadeau has an average return of 2.4% and a 41.88% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.